GXMC
NBIX icon

Global X Management Company’s Neurocrine Biosciences NBIX Stock Holding History

Global X Management Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$989K Buy
10,068
+694
+7% +$62.1K 0.02% 477
2018
Q1 		$777K Buy
9,374
+8,768
+1,447% +$740K 0.02% 490
2017
Q4 		$47K Buy
606
+156
+35% +$10.6K ﹤0.01% 926
2017
Q3 		$28K Buy
450
+14
+3% +$739 ﹤0.01% 1006
2017
Q2 		$20K Buy
+436
New +$21.1K ﹤0.01% 1152

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Global X Management Company's NBIX Position: Q2 2018 in Review

Global X Management Company increased its Neurocrine Biosciences (NBIX) stake by 7.4% in Q2 2018, buying an estimated $62.1K and bringing the position to 10,068 shares worth $989K. The position accounts for 0.02% of the portfolio, ranked #477.

Global X Management Company first reported a position in NBIX in Q2 2017 and has held it in 5 quarters since. 274 funds tracked by Wall St. Rank hold NBIX as of Q2 2018.

  • Global X Management Company held 10,068 shares of Neurocrine Biosciences worth $989K as of Q2 2018.
  • Global X Management Company bought 694 Neurocrine Biosciences shares in Q2 2018, an estimated $62.1K.
  • Neurocrine Biosciences made up 0.02% of Global X Management Company's portfolio in Q2 2018, its #477 holding.
  • Global X Management Company first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 5 quarters since.
  • 274 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.